Design, Synthesis, And Repurposing Of Rosmarinic Acid-Β-:@0.104762:0.111208:0.833107:0.111208:0.833107:0.083261:0.104762:0.083261:0.020619:0.012680:0.011109:0.007939:0.014279:0.015878:0.007140:0.007140:0.015878:0.014279:0.015878:0.009510:0.015878:0.012680:0.011109:0.007939:0.011109:0.007140:0.005583:0.020619:0.015878:0.015878:0.007140:0.020619:0.012680:0.015878:0.015878:0.012680:0.015878:0.014279:0.011109:0.007939:0.015878:0.014279:0.007140:0.022218:0.009510:0.007140:0.020619:0.014279:0.011109:0.023789:0.014279:0.012680:0.007939:0.015878:0.007939:0.012680:0.005580:0.020619:0.012680:0.007939:0.015878:0.009510:0.019048:0.009510
Amino-Α-Ketoamide Hybrids As Antileishmanial Agents   :@0.104762:0.137337:0.814790:0.137337:0.814790:0.109391:0.104762:0.109391:0.020619:0.023789:0.007939:0.015878:0.014279:0.009510:0.020619:0.009510:0.022218:0.012680:0.009510:0.014279:0.014279:0.023789:0.007939:0.015878:0.012680:0.007140:0.022218:0.014279:0.015878:0.012680:0.007939:0.015878:0.011109:0.005560:0.020619:0.011109:0.005572:0.020619:0.015878:0.009510:0.007939:0.007939:0.012680:0.007939:0.011109:0.015878:0.023789:0.014279:0.015878:0.007939:0.014279:0.007939:0.005560:0.020619:0.014279:0.012680:0.015878:0.009510:0.011109:0.007140:0.007140:0.007140
Pharmaceuticals. 2023; 16(11): 1594.:@0.318070:0.161953:0.681929:0.161953:0.681929:0.139687:0.318070:0.139687:0.014370:0.013076:0.011759:0.009149:0.018297:0.011759:0.010442:0.010442:0.013076:0.006538:0.006538:0.010442:0.011759:0.006538:0.009149:0.005880:0.005880:0.011759:0.011759:0.011759:0.011759:0.007832:0.005880:0.011759:0.011759:0.007832:0.010447:0.011759:0.007832:0.007832:0.005880:0.011759:0.011759:0.011759:0.011759:0.005880
------------------------------------------------------------------------------------:@0.171056:0.188078:0.828915:0.188078:0.828915:0.165678:0.171056:0.165678:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832
Ahmed H.e. Hassan, Waleed A. Bayoumi, Selwan M El-Sayed, Trong-Nhat Phan, :@0.110685:0.214144:0.895124:0.214144:0.895124:0.192195:0.110685:0.192195:0.015463:0.012889:0.018036:0.010293:0.011591:0.005796:0.018036:0.005796:0.010293:0.005796:0.005796:0.018036:0.011591:0.009018:0.009018:0.011591:0.012889:0.005796:0.005376:0.018894:0.011591:0.006445:0.010293:0.010293:0.011591:0.004936:0.015463:0.005796:0.005796:0.015463:0.011591:0.010293:0.011591:0.012889:0.018036:0.006445:0.005796:0.005796:0.012889:0.010293:0.006445:0.015463:0.011591:0.012889:0.005796:0.020609:0.005796:0.015463:0.006445:0.007720:0.012889:0.011591:0.010293:0.010293:0.011591:0.005796:0.005796:0.013300:0.009018:0.011591:0.012889:0.011591:0.007720:0.016738:0.012889:0.011591:0.006445:0.005796:0.014165:0.012889:0.011591:0.012889:0.005796:0.005796
Taegeun Oh, Gyeongpyo Ham, Kazem Mahmoud, Joo Hwan No, Yong Sup Lee:@0.121627:0.240272:0.878351:0.240272:0.878351:0.218324:0.121627:0.218324:0.012034:0.011591:0.010293:0.011591:0.010293:0.012889:0.012889:0.005796:0.016738:0.012889:0.005796:0.005796:0.016738:0.010293:0.010293:0.011591:0.012889:0.011591:0.011591:0.010293:0.011591:0.005796:0.018036:0.011591:0.018036:0.005796:0.005796:0.015463:0.011591:0.009018:0.010293:0.018036:0.005796:0.020609:0.011591:0.012889:0.018036:0.011591:0.012889:0.011591:0.005796:0.005796:0.011591:0.011591:0.011591:0.005796:0.018036:0.015463:0.011591:0.012889:0.005796:0.016738:0.011591:0.005796:0.005376:0.011591:0.011591:0.012889:0.011591:0.005796:0.012889:0.012889:0.011591:0.005796:0.014165:0.010293:0.010293
Faculty of Pharmacy Newsletter:@0.147970:0.965677:0.401979:0.965677:0.401979:0.947594:0.147970:0.947594:0.011291:0.009239:0.008205:0.010274:0.005137:0.006153:0.009239:0.004620:0.009239:0.006153:0.004620:0.011291:0.010274:0.009239:0.008205:0.015393:0.009239:0.008205:0.009239:0.004620:0.013342:0.008205:0.013342:0.007188:0.005137:0.008205:0.006153:0.006153:0.008205:0.008205
Reference::@0.104524:0.585391:0.210310:0.585391:0.210310:0.563124:0.104524:0.563124:0.015687:0.010442:0.007832:0.010442:0.009149:0.010442:0.013076:0.010442:0.010442:0.007832
https://doi.org/10.3390/ph16111594 :@0.104524:0.604920:0.349830:0.604920:0.349830:0.588920:0.104524:0.588920:0.008399:0.004670:0.004670:0.008399:0.006535:0.004670:0.004670:0.004670:0.008399:0.008399:0.004670:0.004200:0.008399:0.005277:0.008399:0.004670:0.008399:0.008399:0.004200:0.008399:0.008399:0.008399:0.008399:0.004670:0.008399:0.008399:0.008399:0.008399:0.007771:0.007775:0.008399:0.008399:0.008399:0.008399:0.004200
Abstract:@0.104762:0.328980:0.213026:0.328980:0.213026:0.301034:0.104762:0.301034:0.020905:0.016164:0.011395:0.009795:0.012965:0.014565:0.012965:0.009510
A  series  of  rosmarinic  acid-β-amino-α-ketoamide  hybrids  were  synthesized  and  rationally :@0.104762:0.350571:0.900368:0.350571:0.900368:0.331372:0.104762:0.331372:0.013647:0.005040:0.005735:0.008043:0.009152:0.006914:0.005806:0.009152:0.008043:0.005040:0.005733:0.010281:0.006914:0.005040:0.005733:0.006914:0.010281:0.008043:0.015885:0.009152:0.006914:0.005806:0.010281:0.005806:0.009152:0.005040:0.005733:0.009152:0.009152:0.005806:0.010281:0.006914:0.010462:0.006914:0.009152:0.015885:0.005806:0.010281:0.010281:0.006914:0.010765:0.006914:0.010281:0.009152:0.005806:0.010281:0.009152:0.015885:0.005806:0.010281:0.009152:0.005040:0.005735:0.010281:0.010281:0.010281:0.006914:0.005806:0.010281:0.008043:0.005040:0.005735:0.014756:0.009152:0.006914:0.009152:0.005040:0.005735:0.008043:0.010281:0.010281:0.005806:0.010281:0.009152:0.008043:0.005806:0.009152:0.009152:0.010281:0.005040:0.005733:0.009152:0.010281:0.010281:0.005040:0.005735:0.006914:0.009152:0.005806:0.005806:0.010281:0.010281:0.009152:0.005806:0.005806:0.010079:0.005040
repurposed towards the identification of new antileishmanial hit compounds. Two hybrids, 2g :@0.104762:0.367676:0.900344:0.367676:0.900344:0.348476:0.104762:0.348476:0.006914:0.009152:0.010281:0.010281:0.006914:0.010281:0.010281:0.008043:0.009152:0.010281:0.006854:0.005806:0.010281:0.014756:0.009152:0.006914:0.010281:0.008043:0.006854:0.005806:0.010281:0.009152:0.006854:0.005806:0.010281:0.009152:0.010281:0.005806:0.005806:0.006914:0.005806:0.009152:0.009152:0.005806:0.005806:0.010281:0.010281:0.006854:0.010281:0.006914:0.006854:0.010281:0.009152:0.014756:0.006854:0.009152:0.010281:0.005806:0.005806:0.005806:0.009152:0.005806:0.008043:0.010281:0.015885:0.009152:0.010281:0.005806:0.009152:0.005806:0.006854:0.010281:0.005806:0.005806:0.006854:0.009152:0.010281:0.015885:0.010281:0.010281:0.010281:0.010281:0.010281:0.008043:0.005241:0.006489:0.011107:0.014756:0.010281:0.006854:0.010281:0.010281:0.010281:0.006914:0.005806:0.010281:0.008043:0.005241:0.006854:0.010281:0.010079:0.005040
and 2h, showed promising activity (IC50 values of 9.5 and 8.8 μM against Leishmania donovani :@0.104762:0.384780:0.900338:0.384780:0.900338:0.365580:0.104762:0.365580:0.009152:0.010281:0.010281:0.004794:0.010281:0.010281:0.005241:0.004796:0.008043:0.010281:0.010281:0.014756:0.009152:0.010281:0.004794:0.010281:0.006914:0.010281:0.015885:0.005806:0.008043:0.005806:0.010281:0.010281:0.004796:0.009152:0.009152:0.005806:0.005806:0.010281:0.005806:0.005806:0.010281:0.004794:0.006914:0.006914:0.013647:0.010281:0.010281:0.004796:0.010281:0.009152:0.005806:0.010281:0.009152:0.008043:0.004796:0.010281:0.006914:0.004794:0.010281:0.005241:0.010281:0.004794:0.009152:0.010281:0.010281:0.004794:0.010281:0.005241:0.010281:0.004796:0.011007:0.018123:0.004794:0.009152:0.010281:0.009152:0.005806:0.010281:0.008043:0.005806:0.004794:0.012519:0.009152:0.005806:0.008043:0.010281:0.015885:0.009152:0.010281:0.005806:0.009152:0.004796:0.010281:0.010281:0.010281:0.010281:0.010281:0.009152:0.010281:0.005600:0.005040
promastigotes, respectively).  Their  activities  were comparable to erufosine. In addition, :@0.104762:0.401884:0.900438:0.401884:0.900438:0.382685:0.104762:0.382685:0.010281:0.006914:0.010281:0.015885:0.009152:0.008043:0.005806:0.005806:0.010281:0.010281:0.005806:0.009152:0.008043:0.005241:0.012720:0.006914:0.009152:0.008043:0.010281:0.009152:0.009152:0.005806:0.005806:0.010281:0.009152:0.005806:0.010281:0.006914:0.005241:0.005040:0.007308:0.012519:0.010281:0.009152:0.005806:0.006914:0.005040:0.007670:0.009152:0.009152:0.005806:0.005806:0.010281:0.005806:0.005806:0.005806:0.009152:0.008043:0.005040:0.007670:0.014756:0.009152:0.006914:0.009152:0.012720:0.009152:0.010281:0.015885:0.010281:0.009152:0.006914:0.009152:0.010281:0.005806:0.009152:0.012720:0.005806:0.010281:0.012720:0.009152:0.006914:0.010281:0.006914:0.010281:0.008043:0.005806:0.010281:0.009152:0.005241:0.012720:0.006914:0.010281:0.012720:0.009152:0.010281:0.010281:0.005806:0.005806:0.005806:0.010281:0.010281:0.005042:0.005040
cytotoxicity evaluation employing human THP-1 cells revealed that the two hybrids 2g and :@0.104762:0.418989:0.900348:0.418989:0.900348:0.399789:0.104762:0.399789:0.009152:0.010281:0.005806:0.010281:0.005806:0.010281:0.010281:0.005806:0.009152:0.005806:0.005806:0.010281:0.008285:0.009152:0.010281:0.009152:0.005806:0.010281:0.009152:0.005806:0.005806:0.010281:0.010281:0.008285:0.009152:0.015885:0.010281:0.005806:0.010281:0.010281:0.005806:0.010281:0.010281:0.008285:0.010281:0.010281:0.015885:0.009152:0.010281:0.007924:0.012519:0.014756:0.011410:0.006914:0.010281:0.008285:0.009152:0.009152:0.005806:0.005806:0.008043:0.008285:0.006914:0.009152:0.010281:0.009152:0.009152:0.005806:0.009152:0.010281:0.008285:0.005806:0.010281:0.009152:0.005806:0.008285:0.005806:0.010281:0.009152:0.008285:0.005806:0.014756:0.010281:0.008285:0.010281:0.010281:0.010281:0.006914:0.005806:0.010281:0.008043:0.008285:0.010281:0.010281:0.008285:0.009152:0.010281:0.010079:0.005040
2h possess no cytotoxic effects up to 100 µM, while erufosine possessed cytotoxicity with :@0.104762:0.436093:0.900223:0.436093:0.900223:0.416894:0.104762:0.416894:0.010281:0.010281:0.008769:0.010281:0.010281:0.008043:0.008043:0.009152:0.008043:0.008043:0.008769:0.010281:0.010281:0.008769:0.009152:0.010281:0.005806:0.010281:0.005806:0.010281:0.010281:0.005806:0.009152:0.008769:0.009152:0.006550:0.006914:0.009152:0.009152:0.005806:0.008043:0.008769:0.010281:0.010281:0.008769:0.005806:0.010281:0.008769:0.010281:0.010281:0.010281:0.008769:0.011813:0.018123:0.005241:0.008769:0.014756:0.010281:0.005806:0.005806:0.009152:0.008769:0.009152:0.006914:0.010281:0.006914:0.010281:0.008043:0.005806:0.010281:0.009152:0.008769:0.010281:0.010281:0.008043:0.008043:0.009152:0.008043:0.008043:0.009152:0.010281:0.008769:0.009152:0.010281:0.005806:0.010281:0.005806:0.010281:0.010281:0.005806:0.009152:0.005806:0.005806:0.010281:0.008769:0.014756:0.005806:0.005806:0.010079:0.005040
CC50 value of 19.4 µM. In silico docking provided insights into structure–activity relationship :@0.104762:0.453198:0.900346:0.453198:0.900346:0.433998:0.104762:0.433998:0.013647:0.013647:0.010281:0.010281:0.005765:0.010281:0.009152:0.005806:0.010281:0.009152:0.005765:0.010281:0.006914:0.005765:0.010281:0.010281:0.005241:0.010281:0.005765:0.011813:0.018123:0.005241:0.005765:0.006914:0.010281:0.005765:0.008043:0.005806:0.005806:0.005806:0.009152:0.010281:0.005765:0.010281:0.010281:0.009152:0.010281:0.005806:0.010281:0.010281:0.005765:0.010281:0.006914:0.010281:0.010281:0.005806:0.010281:0.009152:0.010281:0.005765:0.005806:0.010281:0.008043:0.005806:0.010281:0.010281:0.005806:0.008043:0.005765:0.005806:0.010281:0.005806:0.010281:0.005765:0.008043:0.005806:0.006914:0.010281:0.009152:0.005806:0.010281:0.006914:0.009152:0.010281:0.009152:0.009152:0.005806:0.005806:0.010281:0.005806:0.005806:0.010281:0.005765:0.006914:0.009152:0.005806:0.009152:0.005806:0.005806:0.010281:0.010281:0.008043:0.010281:0.005806:0.010079:0.005040
emphasizing the importance of the aliphatic chain at the α-carbon of the cinnamoyl carbonyl :@0.104762:0.470302:0.900404:0.470302:0.900404:0.451102:0.104762:0.451102:0.009152:0.015885:0.010281:0.010281:0.009152:0.008043:0.005806:0.009152:0.005806:0.010281:0.010281:0.007304:0.005806:0.010281:0.009152:0.007304:0.005806:0.015885:0.010281:0.010281:0.006914:0.005806:0.009152:0.010281:0.009152:0.009152:0.007304:0.010281:0.006914:0.007304:0.005806:0.010281:0.009152:0.007304:0.009152:0.005806:0.005806:0.010281:0.010281:0.009152:0.005806:0.005806:0.009152:0.007306:0.009152:0.010281:0.009152:0.005806:0.010281:0.007304:0.009152:0.005806:0.007304:0.005806:0.010281:0.009152:0.007306:0.010765:0.006914:0.009152:0.009152:0.006914:0.010281:0.010281:0.010281:0.007304:0.010281:0.006914:0.007304:0.005806:0.010281:0.009152:0.007304:0.009152:0.005806:0.010281:0.010281:0.009152:0.015885:0.010281:0.010281:0.005806:0.007304:0.009152:0.009152:0.006914:0.010281:0.010281:0.010281:0.010281:0.005600:0.005040
group establishing favorable binding interactions with LdCALP and LARG in both hybrids 2g :@0.104762:0.487406:0.900408:0.487406:0.900408:0.468207:0.104762:0.468207:0.010281:0.006914:0.010281:0.010281:0.010281:0.006249:0.009152:0.008043:0.005806:0.009152:0.010281:0.005806:0.005806:0.008043:0.010281:0.005806:0.010281:0.010281:0.006249:0.006914:0.009152:0.010281:0.010281:0.006914:0.009152:0.010281:0.005806:0.009152:0.006249:0.010281:0.005806:0.010281:0.010281:0.005806:0.010281:0.010281:0.006249:0.005806:0.010281:0.005806:0.009152:0.006914:0.009152:0.009152:0.005806:0.005806:0.010281:0.010281:0.008043:0.006249:0.014756:0.005806:0.005806:0.010281:0.006249:0.012519:0.010281:0.013647:0.014756:0.012519:0.010666:0.006249:0.009152:0.010281:0.010281:0.006249:0.012519:0.014756:0.013647:0.014756:0.006249:0.005806:0.010281:0.006249:0.010281:0.010281:0.005806:0.010281:0.006249:0.010281:0.010281:0.010281:0.006914:0.005806:0.010281:0.008043:0.006249:0.010281:0.010079:0.005040
and 2h. In light of these findings, hybrids 2g and 2h are suggested as potential safe antileishmanial :@0.104762:0.504511:0.900463:0.504511:0.900463:0.485311:0.104762:0.485311:0.009152:0.010281:0.010281:0.003699:0.010281:0.010281:0.005241:0.003709:0.006914:0.010281:0.003699:0.005806:0.005806:0.010281:0.010281:0.005806:0.003699:0.010281:0.006914:0.003709:0.005806:0.010281:0.009152:0.008043:0.009152:0.003709:0.006914:0.005806:0.010281:0.010281:0.005806:0.010281:0.010281:0.008043:0.005241:0.003709:0.010281:0.010281:0.010281:0.006914:0.005806:0.010281:0.008043:0.003709:0.010281:0.010281:0.003709:0.009152:0.010281:0.010281:0.003709:0.010281:0.010281:0.003709:0.009152:0.006914:0.009152:0.003709:0.008043:0.010281:0.010281:0.010281:0.009152:0.008043:0.005806:0.009152:0.010281:0.003709:0.009152:0.008043:0.003699:0.010281:0.010281:0.005806:0.009152:0.010281:0.005806:0.005806:0.009152:0.005806:0.003709:0.008043:0.009152:0.006914:0.009152:0.003709:0.009152:0.010281:0.005806:0.005806:0.005806:0.009152:0.005806:0.008043:0.010281:0.015885:0.009152:0.010281:0.005806:0.009152:0.005600:0.005040
hit compounds for further development of anti-leishmanial agents.:@0.104762:0.521615:0.670133:0.521615:0.670133:0.502415:0.104762:0.502415:0.010281:0.005806:0.005806:0.007701:0.009152:0.010281:0.015885:0.010281:0.010281:0.010281:0.010281:0.010281:0.008043:0.007701:0.006914:0.010281:0.006914:0.007701:0.006914:0.010281:0.006914:0.005806:0.010281:0.009152:0.006914:0.007701:0.010281:0.009152:0.010281:0.009152:0.005806:0.010281:0.010281:0.015885:0.009152:0.010281:0.005806:0.007701:0.010281:0.006914:0.007701:0.009152:0.010281:0.005806:0.005806:0.006914:0.005806:0.009152:0.005806:0.008043:0.010281:0.015885:0.009152:0.010281:0.005806:0.009152:0.005806:0.007701:0.009152:0.010281:0.009152:0.010281:0.005806:0.008043:0.005040
110:@0.085714:0.970956:0.135335:0.970956:0.135335:0.940018:0.085714:0.940018:0.016540:0.016540:0.016540
Chapter V:@0.103809:0.063855:0.209433:0.063855:0.209433:0.040840:0.103809:0.040840:0.016980:0.013076:0.011759:0.013076:0.007832:0.010442:0.010021:0.005456:0.016980